Do analysts prefer ASBP or CLNN?

Clene has a consensus target price of $34.00, indicating a potential upside of 936.59%. Given Clene's stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Is ASBP or CLNN more profitable?

Aspire Biopharma has a net margin of -11,362.21% compared to Clene's net margin of -20,063.96%. Company Net Margins Return on Equity Return on Assets Aspire Biopharma -11,362.21% N/A -177.59% Clene -20,063.96% N/A -137.04%

Does the media refer more to ASBP or CLNN?

In the previous week, Aspire Biopharma had 4 more articles in the media than Clene. MarketBeat recorded 6 mentions for Aspire Biopharma and 2 mentions for Clene. Clene's average media sentiment score of 0.94 beat Aspire Biopharma's score of 0.75 indicating that Clene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ASBP or SCLX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ASBP or SCLX more profitable?

Scilex has a net margin of -1,414.57% compared to Aspire Biopharma's net margin of -11,362.21%. Company Net Margins Return on Equity Return on Assets Aspire Biopharma -11,362.21% N/A -177.59% Scilex -1,414.57% N/A -147.00%

Do analysts recommend ASBP or VERU?

Veru has a consensus target price of $24.50, indicating a potential upside of 947.01%. Given Veru's stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Veru 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger earnings & valuation, ASBP or VERU?

Veru has higher revenue and earnings than Aspire Biopharma. Veru is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aspire Biopharma $10K 1,240.40 -$24.48M -$69.62 N/A Veru $16.89M 2.36 -$22.73M -$0.69 N/A

Is ASBP or VERU more profitable?

Veru has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%. Aspire Biopharma's return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Aspire Biopharma -11,362.21% N/A -177.59% Veru N/A -47.58% -35.83%

Does the media refer more to ASBP or VERU?

In the previous week, Aspire Biopharma and Aspire Biopharma both had 6 articles in the media. Aspire Biopharma's average media sentiment score of 0.75 beat Veru's score of 0.16 indicating that Aspire Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veru 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate ASBP or GRCE?

Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 162.01%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Grace Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate ASBP or VIRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Aspire Biopharma (ASBP) Competitors

$8.86 -0.20 (-2.21%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$8.54 -0.32 (-3.56%)

As of 06:12 AM Eastern

Compare

ASBP vs. CLNN, SCLX, VERU, GRCE, and VIRI

Should you buy Aspire Biopharma stock or one of its competitors? Aspire Biopharma's main competitors and comparable companies include Clene (CLNN), Scilex (SCLX), Veru (VERU), Grace Therapeutics (GRCE), and Virios Therapeutics (VIRI). Companies are selected based on similarities in market, industry, and size.

How does Aspire Biopharma compare to Clene?

Aspire Biopharma (NASDAQ:ASBP) and Clene (NASDAQ:CLNN) are related small-cap companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Aspire Biopharma had 4 more articles in the media than Clene. MarketBeat recorded 6 mentions for Aspire Biopharma and 2 mentions for Clene. Clene's average media sentiment score of 0.94 beat Aspire Biopharma's score of 0.75 indicating that Clene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by insiders. Comparatively, 28.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aspire Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Clene has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Clene has a consensus target price of $34.00, indicating a potential upside of 936.59%. Given Clene's stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Aspire Biopharma has a net margin of -11,362.21% compared to Clene's net margin of -20,063.96%.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	-11,362.21%	N/A	-177.59%
Clene	-20,063.96%	N/A	-137.04%

Aspire Biopharma has higher earnings, but lower revenue than Clene. Clene is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	1,240.40	-$24.48M	-$69.62	N/A
Clene	$197K	213.93	-$26.17M	-$3.50	N/A

Summary

Clene beats Aspire Biopharma on 10 of the 15 factors compared between the two stocks.

How does Aspire Biopharma compare to Scilex?

Aspire Biopharma (NASDAQ:ASBP) and Scilex (NASDAQ:SCLX) are related small-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

In the previous week, Aspire Biopharma had 5 more articles in the media than Scilex. MarketBeat recorded 6 mentions for Aspire Biopharma and 1 mentions for Scilex. Scilex's average media sentiment score of 1.89 beat Aspire Biopharma's score of 0.75 indicating that Scilex is being referred to more favorably in the news media.

Company	Overall Sentiment
Aspire Biopharma	Positive
Scilex	Very Positive

Aspire Biopharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market. Comparatively, Scilex has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

Aspire Biopharma has higher earnings, but lower revenue than Scilex. Aspire Biopharma is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	1,240.40	-$24.48M	-$69.62	N/A
Scilex	$30.25M	1.43	-$358.73M	-$49.70	N/A

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 4.5% of Scilex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scilex has a net margin of -1,414.57% compared to Aspire Biopharma's net margin of -11,362.21%.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	-11,362.21%	N/A	-177.59%
Scilex	-1,414.57%	N/A	-147.00%

Summary

Scilex beats Aspire Biopharma on 8 of the 12 factors compared between the two stocks.

How does Aspire Biopharma compare to Veru?

Aspire Biopharma (NASDAQ:ASBP) and Veru (NASDAQ:VERU) are related small-cap companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Veru has a consensus target price of $24.50, indicating a potential upside of 947.01%. Given Veru's stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Aspire Biopharma and Aspire Biopharma both had 6 articles in the media. Aspire Biopharma's average media sentiment score of 0.75 beat Veru's score of 0.16 indicating that Aspire Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Veru has higher revenue and earnings than Aspire Biopharma. Veru is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	1,240.40	-$24.48M	-$69.62	N/A
Veru	$16.89M	2.36	-$22.73M	-$0.69	N/A

Aspire Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, Veru has a beta of -1.17, suggesting that its stock price is 217% less volatile than the broader market.

Veru has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%. Aspire Biopharma's return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	-11,362.21%	N/A	-177.59%
Veru	N/A	-47.58%	-35.83%

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Veru beats Aspire Biopharma on 10 of the 15 factors compared between the two stocks.

How does Aspire Biopharma compare to Grace Therapeutics?

Aspire Biopharma (NASDAQ:ASBP) and Grace Therapeutics (NASDAQ:GRCE) are related small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Grace Therapeutics has lower revenue, but higher earnings than Aspire Biopharma. Grace Therapeutics is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	1,240.40	-$24.48M	-$69.62	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Grace Therapeutics has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%. Aspire Biopharma's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	-11,362.21%	N/A	-177.59%
Grace Therapeutics	N/A	-36.11%	-34.39%

In the previous week, Aspire Biopharma had 5 more articles in the media than Grace Therapeutics. MarketBeat recorded 6 mentions for Aspire Biopharma and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.91 beat Aspire Biopharma's score of 0.75 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aspire Biopharma	Positive
Grace Therapeutics	Very Positive

Aspire Biopharma has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Grace Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 162.01%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Grace Therapeutics beats Aspire Biopharma on 10 of the 15 factors compared between the two stocks.

How does Aspire Biopharma compare to Virios Therapeutics?

Aspire Biopharma (NASDAQ:ASBP) and Virios Therapeutics (NASDAQ:VIRI) are related small-cap companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Virios Therapeutics has lower revenue, but higher earnings than Aspire Biopharma. Virios Therapeutics is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	1,240.40	-$24.48M	-$69.62	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virios Therapeutics has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%. Aspire Biopharma's return on equity of 0.00% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	-11,362.21%	N/A	-177.59%
Virios Therapeutics	N/A	-130.33%	-115.00%

Aspire Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

In the previous week, Aspire Biopharma had 6 more articles in the media than Virios Therapeutics. MarketBeat recorded 6 mentions for Aspire Biopharma and 0 mentions for Virios Therapeutics. Aspire Biopharma's average media sentiment score of 0.75 beat Virios Therapeutics' score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Aspire Biopharma	Positive
Virios Therapeutics	Neutral

Summary

Aspire Biopharma beats Virios Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Aspire Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASBP vs. The Competition

Export

Metric	Aspire Biopharma	Automobile Components Industry	Consumer Discretionary Sector	NASDAQ Exchange
Market Cap	$12.71M	$4.92B	$12.70B	$14.30B
Dividend Yield	N/A	2.28%	58.24%	11.70%
P/E Ratio	-0.13	10.79	44.58	25.37
Price / Sales	1,240.40	41.16	92.85	87.69
Price / Cash	N/A	10.90	18.49	34.96
Price / Book	-0.16	1.74	4.09	6.24
Net Income	-$24.48M	$70.95M	$445.74M	$358.08M
7 Day Performance	0.11%	-2.57%	-1.48%	-0.70%
1 Month Performance	12.87%	-3.51%	-4.22%	-2.76%
1 Year Performance	-98.21%	1.49%	-6.66%	6.72%

Aspire Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASBP Aspire Biopharma	0.7854 of 5 stars	$8.86 -2.2%	N/A	-98.3%	$12.71M	$10K	N/A	N/A	Short Interest Decrease
CLNN Clene	2.062 of 5 stars	$3.85 -3.5%	$33.25 +763.6%	-43.4%	$49.47M	$200K	N/A	100
SCLX Scilex	0.6215 of 5 stars	$5.41 +2.5%	N/A	-80.6%	$45.99M	$31.61M	N/A	80	Positive News
VERU Veru	2.7119 of 5 stars	$2.64 -0.4%	$24.50 +828.0%	-32.2%	$45.01M	N/A	N/A	230
GRCE Grace Therapeutics	2.1223 of 5 stars	$2.10 -1.9%	$6.00 +185.7%	-27.3%	$44.18M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASBP) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aspire Biopharma (ASBP) Competitors

ASBP vs. CLNN, SCLX, VERU, GRCE, and VIRI

How does Aspire Biopharma compare to Clene?

Summary

How does Aspire Biopharma compare to Scilex?

Summary

How does Aspire Biopharma compare to Veru?

Summary

How does Aspire Biopharma compare to Grace Therapeutics?

Summary

How does Aspire Biopharma compare to Virios Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aspire Biopharma (ASBP) Competitors

ASBP vs. CLNN, SCLX, VERU, GRCE, and VIRI

How does Aspire Biopharma compare to Clene?

Does the media refer more to ASBP or CLNN?

Do insiders and institutionals have more ownership in ASBP or CLNN?

Which has more risk & volatility, ASBP or CLNN?

Do analysts prefer ASBP or CLNN?

Is ASBP or CLNN more profitable?

Which has stronger earnings and valuation, ASBP or CLNN?

Summary

How does Aspire Biopharma compare to Scilex?

Does the media refer more to ASBP or SCLX?

Which has more volatility & risk, ASBP or SCLX?

Which has higher earnings and valuation, ASBP or SCLX?

Do institutionals and insiders believe in ASBP or SCLX?

Do analysts recommend ASBP or SCLX?

Is ASBP or SCLX more profitable?

Summary

How does Aspire Biopharma compare to Veru?

Do analysts recommend ASBP or VERU?

Does the media refer more to ASBP or VERU?

Which has stronger earnings & valuation, ASBP or VERU?

Which has more risk & volatility, ASBP or VERU?

Is ASBP or VERU more profitable?

Do insiders & institutionals believe in ASBP or VERU?

Summary

How does Aspire Biopharma compare to Grace Therapeutics?

Which has better valuation & earnings, ASBP or GRCE?

Do institutionals & insiders hold more shares of ASBP or GRCE?

Is ASBP or GRCE more profitable?

Does the media refer more to ASBP or GRCE?

Which has more risk & volatility, ASBP or GRCE?

Do analysts rate ASBP or GRCE?

Summary

How does Aspire Biopharma compare to Virios Therapeutics?

Do institutionals and insiders believe in ASBP or VIRI?

Which has higher valuation & earnings, ASBP or VIRI?

Do analysts rate ASBP or VIRI?

Is ASBP or VIRI more profitable?

Which has more risk and volatility, ASBP or VIRI?

Does the media refer more to ASBP or VIRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools